Favimol Favipiravir

 Favipiravir (T-705) is an engineered prodrug, first found while evaluating the antiviral action of substance specialists dynamic against the flu infection in the compound library of Toyoma synthetics. A lead compound, A/PR/8/34, later assigned as T-1105, and its subordinates were found to have antiviral exercises. Favipiravir is determined by synthetic alteration of the pyrazine moiety of T-1105 (Fig. 1).2 It has been affirmed in Japan for the administration of arising pandemic flu contaminations in 2014.

  The  COVID-19  pandemic  became  the  worst  public-health  epidemic  in  a  century,  six  months  and  more  than  16  million  reported  cases  later.  A  long  and  arduous  timeline  will  include  finding  a  new  and  specific  antiviral  agent  against  SARS-CoV-2.  Thus,  repurposed  medications,  already  in  use  against  other  viral  infections,  have  been  forced  into  rapid  action  by  necessity.  Favipiravir,  initially  marketed  in  Japan  as  an  anti-influenza  agent,  is  one  such  drug.